Clinical Trials & Medical Discoveries The most recent news and results from scientific and medical research, covering all aspects of healthcare, including testing, diagnosis, and treatment. Stay up-to-date on the latest medical discoveries and breakthroughs with announcements of new products to be tested, upcoming clinical trials and studies, and newly published results. Also included are updates regarding funding decisions, company performance, and legal news.

Latest

26 Apr, 2017, 16:13 ET FH Foundation's FOCUS analysis shows that regardless of medical need, prescriptions for PCSK9 inhibitors are being rejected at high rates

The Familial Hypercholesterolemia Foundation today published a study in Circulation revealing high rejection rates for PCSK9 inhibitors in the two...


26 Apr, 2017, 16:05 ET Jazz Pharmaceuticals Announces Positive Results from the Phase 3 TONES 2 Study of JZP-110 in Narcolepsy Patients with Excessive Sleepiness

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive efficacy results from the global multicenter study of JZP-110 in adult patients...


26 Apr, 2017, 13:55 ET Braeburn Pharmaceuticals Achieves Primary Endpoint in Pivotal Phase 2/3 Study of BB0817, Risperidone 6-month Implant for Treatment of Schizophrenia

Braeburn Pharmaceuticals announced today that a 6-month study of the safety, tolerability and pharmacokinetics of transferring patients diagnosed...


26 Apr, 2017, 09:00 ET electroCore Announces Data Presentation at the 69th American Academy of Neurology Annual Meeting

electroCore, a neuroscience and technology company dedicated to improving patient outcomes through technological advancement, announced today that...


26 Apr, 2017, 09:00 ET Research Grants Available for Rare Diseases from National Organization for Rare Disorders (NORD)

The National Organization for Rare Disorders (NORD), the leading independent nonprofit organization representing the 30 million Americans with rare...


26 Apr, 2017, 08:32 ET New Clinical Study Demonstrates Benefits of RESPeRATE for Heart Failure Patients

2breathe Technologies Ltd. with its wholly owned U.S. subsidiary Resperate Inc. announced, today, the publication of a new peer reviewed original...


26 Apr, 2017, 08:30 ET Entest BioMedical's Chairman Discusses its Subsidiary, Zander Therapeutics, Inc.'s Progress With Small Molecule Immunotherapies for Treating Cancer and Arthritis in Dogs

Entest BioMedical Inc.'s (OTCPINK: ENTB) Chairman and CEO David Koos discussed current and anticipated developments for the company's subsidiary,...


26 Apr, 2017, 08:00 ET DarioHealth Expands Global Presence With Direct-to-Consumer Launch in the U.K.

DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today announced the launch of...


26 Apr, 2017, 07:00 ET Mercator MedSystems Announces First Enrollment in the TANGO Trial for BTK Vascular Disease

Mercator MedSystems, Inc., a medical technology company, announced today the first patient enrollment into the TANGO (Temsirolimus Adventitial...


26 Apr, 2017, 07:00 ET Asterias Announces Publication of Positive Phase 2 Data on AST-VAC1 for the Treatment of Acute Myeloid Leukemia (AML) in 'Cancer'

Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced...


26 Apr, 2017, 05:24 ET Nuovo studio dimostra che le microsfere in resina SIR-Spheres® con Y-90 migliorano notevolmente la qualità della sopravvivenza nel tumore primario al fegato rispetto al trattamento standard

Lo studio SARAH condotto su 459 pazienti dimostra che trattamenti locali del carcinoma epatocellulare (HCC) avanzato o inoperabile con microsfere...


26 Apr, 2017, 05:00 ET HIPPO's Molecular Balancing Act Helps Nerves Not Short Circuit

Scientists write in Nature Communications it may be possible to therapeutically fine tune a constantly shifting balance of molecular signals to...


26 Apr, 2017, 03:36 ET Las microesferas SIR-Spheres® Y-90 mejoran la calidad en la supervivencia del HCC frente al tratamiento estándar

Las microesferas de resina SIR-Spheres® Y-90 consiguen una mejora sustancial de la calidad de la supervivencia en cáncer de...


26 Apr, 2017, 03:35 ET Nieuw vergelijkend onderzoek toont aan dat SIR-Spheres® Y-90-harsmicrosferen de overlevingskwaliteit ten opzichte van de standaardbehandeling van primaire leverkanker aanzienlijk verbeteren

Het SARAH-onderzoek met 459 patiënten heeft aangetoond dat lokale behandelingen van geavanceerd of inoperabel hepatocellulair carcinoom...


26 Apr, 2017, 03:00 ET First patient treated in Turnstone's lung cancer trial combining novel viral cancer therapy with approved checkpoint inhibitor

Combination of Turnstone's oncolytic viral immunotherapy with checkpoint inhibitors showed promising results in preclinical testing OTTAWA, April...


26 Apr, 2017, 01:00 ET Shire Granted EU Conditional Marketing Authorisation for Natpar[®▼] (Parathyroid Hormone) for the Treatment of Patients with Chronic Hypoparathyroidism

Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that the European Commission (EC) has granted Conditional Marketing Authorisation for Natpar...


25 Apr, 2017, 22:53 ET Global CRO Market to Reach $64.58 Billion by 2021

The Global CRO Market, Forecast to 2021, presents an overview and analysis of the global clinical trials and research outsourcing (CRO) market. It...


25 Apr, 2017, 19:10 ET European Society for Medical Oncology (ESMO): Annual Flu Jab May Pose Greater Risk for Lung Cancer Patients Under Immunotherapy

Lung cancer patients treated with immunotherapy may be at increased risk of adverse events after receiving the seasonal influenza vaccination,...


25 Apr, 2017, 17:51 ET Britannia Pharmaceuticals: Landmark Apomorphine Study Confirms its Established Role as a Highly Effective Treatment for Parkinson's Disease Patients Whose Symptoms Cannot be Controlled on Standard Therapies

Results from the first randomized, controlled trial investigating the efficacy and safety of APO-go®/MOVAPO® (apomorphine) subcutaneous infusion...


25 Apr, 2017, 17:51 ET Britannia Pharmaceuticals: Richtungsweisende Studie bestätigt Rolle von Apomorphin als hocheffektive Behandlung für Parkinson-Erkrankung in Patienten, bei denen Standardtherapien keine ausreichende Symptomkontrolle bieten

Im Rahmen der Sitzung ‚Emerging Science' auf der Jahrestagung der American Academy of Neurology (AAN), die am 25. April 2017 in Boston (USA)...


25 Apr, 2017, 17:51 ET Britannia Pharmaceuticals: une étude phare confirme l'efficacité de l'apomorphine dans le traitement de symptômes de la maladie de Parkinson ne pouvant pas être contrôlés par des traitements standard

Les résultats de l'étude TOLEDO, le premier essai randomisé contrôlé sur l'efficacité et l'innocuité de la perfusion sous-cutanée APO-go®/MOVAPO®...


25 Apr, 2017, 17:51 ET Britannia Pharmaceuticals: La apomorfina confirma efectividad como tratamiento para la enfermedad de Parkinson

- Britannia Pharmaceuticals: Estudio de referencia sobre la apomorfina confirma su papel establecido como un tratamiento altamente efectivo para...


25 Apr, 2017, 13:10 ET The American College of Cardiology & The American Heart Association Partner with Doctor Evidence for Important Guideline Evidence Reviews

The American College of Cardiology and the American Heart Association ("ACC/AHA") published guidelines on lower extremity peripheral artery disease...


25 Apr, 2017, 11:47 ET A Unique Womb-Like Device Could Reduce Mortality and Disability for Extremely Premature Babies

A unique womb-like environment designed by pediatric researchers could transform care for extremely premature babies, by mimicking the prenatal...